NASDAQ:RGC News 7 October 2025 - 2 February 2026

Regencell Bioscience Holdings shares rose about 9.8% to $27.43 by early afternoon Monday, with trading volume reaching roughly 241,000 shares. No new disclosures or statements from the company accompanied the move. Traders are focused on the April 20 lock-up expiry, previously detailed in SEC filings.

Regencell Bioscience shares jumped 16.3% to $35.77 in premarket trading Friday after a 40.4% surge Thursday, with no new company announcements. Thursday’s rally saw heavy volume and wide price swings, closing at $30.77. The company’s filings warn of “extreme price and volume fluctuations” and note it has no saleable products or revenue. Market cap reached about $15.2 billion as of Friday.

Regencell Bioscience shares closed Friday up 10.6% at $45.79 after swinging between $35.13 and $50.92 on heavy volume. The company disclosed a DOJ subpoena and warned of possible legal penalties and funding risks in its Oct. 31 annual report. Its auditor expressed “substantial doubt” about Regencell’s ability to continue as a going concern. No new corporate updates have been posted since the annual filing.

Regencell Bioscience shares jumped 8.5% to $44.96 in midday Friday trading, rebounding from Thursday’s 21.7% drop. The stock has seen heavy swings and trading halts, with no recent company updates. Bragar Eagel & Squire is investigating Regencell on behalf of shareholders. CEO Yat-Gai Au controls about 88.6% of shares, according to SEC filings.

Regencell Bioscience Holdings shares jumped 18.3% to $31.99 in midday Nasdaq trading Tuesday, after swinging between $26.60 and $34.40. No new company statements have been posted since its Oct. 31 annual report, which disclosed a DOJ trading probe and “substantial doubt” about its ability to continue as a going concern. About 850,000 shares changed hands.

Regencell Bioscience Holdings (RGC) surged 14% to $25.25 on Dec. 24, 2025, despite remaining a pre-revenue company. The move followed a ValueWalk article highlighting RGC’s 17,000% gain in 2025, driven by low float, momentum trading, and a recent 38-for-1 stock split. Intraday prices ranged from $22.00 to $26.33. RGC’s market cap neared $11 billion.

Company Profile and Mission Regencell Bioscience is an early-stage biotech company focused on Traditional Chinese Medicine. Headquartered in Causeway Bay, Hong Kong, Regencell researches, develops, and aims to commercialize herbal treatment formulae for neurocognitive disorders – primarily Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) Marketbeat Insidermonkey. The company’s approach is based on the “Sik-Kee Au TCM Brain Theory,” a proprietary herbal methodology developed by the CEO’s father ts2.tech. Founded in 2014 by CEO Yat-Gai Au, Regencell went public on NASDAQ in July 2021 Stockanalysis. The firm positions itself as a socially responsible, mission-driven enterprise: “Our goal is to save and improve the lives of